Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

65.80
-0.1700-0.26%
Post-market: 66.750.9500+1.44%19:33 EDT
Volume:2.82M
Turnover:186.75M
Market Cap:12.88B
PE:-18.44
High:67.32
Open:66.14
Low:65.61
Close:65.97
52wk High:93.42
52wk Low:51.85
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.85
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.12
PE(LYR):-17.38

Loading ...

Barclays Remains a Buy on BridgeBio Pharma (BBIO)

TIPRANKS
·
Yesterday

BridgeBio's Heart Drug Shows Superior Real-World Results Over Pfizer's Rival Treatment

Stock News
·
Sep 24

BridgeBio Real-World Study Shows Attruby Cuts ATTR-CM Clinical Worsening Risk 34% vs Pfizer’s Tafamidis

Reuters
·
Sep 23

BridgeBio CEO Neil Kumar Disposes of Common Shares Worth $691,023.06

Reuters
·
Sep 22

BridgeBio Pharma Reports Inducement RSU Grants for 63,009 Shares to 36 New Hires

Reuters
·
Sep 19

BridgeBio Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 19

Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
Sep 14

BridgeBio Pharma Price Target Maintained with a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 10

BridgeBio Highlights $1.7 Billion Cash Position, Targets Three Potential US Launches by Mid-2027

Reuters
·
Sep 09

BridgeBio Posts Propel 3 Phase 3 Infigratinib Data in Children with Achondroplasia Presentation

Reuters
·
Sep 09

BridgeBio Says FDA Reviews NDA for Infigratinib in Achondroplasia

Reuters
·
Sep 09

BridgeBio Pharma Inc: Submitted an Nda to FDA for Oral Infigratinib in Achondroplasia and Anticipates a U.S. Launch in Mid-2027

THOMSON REUTERS
·
Sep 09

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 Propel 3 Trial

THOMSON REUTERS
·
Sep 09

BridgeBio Pharma, - Oral Infigratinib Shows Favorable Trends Versus Placebo in Sleep Apnea and Otitis Media at 52 Weeks

THOMSON REUTERS
·
Sep 09

BridgeBio Oncology Therapeutics Releases RAS-Pathway Therapeutics Corporate Update Deck

Reuters
·
Sep 09

BridgeBio Pharma (BBIO) Stock Looks Fully Priced Despite Strong Sales Growth

Simply Wall St.
·
Sep 02

BridgeBio Pharma files $500M mixed securities shelf

TIPRANKS
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

BridgeBio Pharma is Maintained at Outperform by Mizuho

Dow Jones
·
Sep 01

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01